Enhanced Sensitivity to Cholecystokinin Tetrapeptide in Panic Disorder: Clinical and Behavioral Findings

doi:10.1001/archpsyc.1991.01810310021005

You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

Vol. 48 No. 7, July 1991

Online Only
	•	Online First Table of Contents

ORIGINAL ARTICLES

•	Online Features

This Article
•	References
•	Full text PDF
•	Reply to article
•	Send to a friend
•	Save in My Folder
•	Save to citation manager
•	Permissions

Citing Articles
•	Citation map
•	Citing articles on HighWire
•	Citing articles on Web of Science (258)
•	Contact me when this article is cited

Related Content
•	Similar articles in this journal

Social Bookmarking
	What's this?

Enhanced Sensitivity to Cholecystokinin Tetrapeptide in Panic Disorder

Clinical and Behavioral Findings

Jacques Bradwejn, MD, FRCPC; Diana Koszycki, MA; Christian Shriqui, MD, FRCPC

Arch Gen Psychiatry. 1991;48(7):603-610.

Abstract

• We studied the action of cholecystokinin tetrapeptide(CCK-4) in patients with panic disorder and normal controls.Subjects received, in random order, one injection of CCK-4 andone injection of placebo (saline) on two separate days in adouble-blind crossover design. Two doses of CCK-4, 50 and 25µg, were administered to two different samples of subjects.The panic rate with 50 µg of CCK-4 was 100% (12/12) forpatients and 47% (7/15) for controls. The panic rate with 25µg of CCK-4 was 91% (10/11) for patients and 17% (2/12)for controls. Nine percent of patients compared with 0% of controlspanicked with placebo. These findings concur with previous reportsof a panicogenic effect of CCK-4 and suggest that patients withpanic disorder are more sensitive to the panicogenic effectof the peptide than are normal controls.

Author Affiliations

From the Psychopharmacology Division, St Mary's Hospital Center, and Department of Psychiatry, McGill University, Montreal, Quebec.

Footnotes

Accepted for publication October 17, 1990.

Read in part at the annual meetings of the American PsychiatricAssociation, San Francisco, Calif, May 11,1989, and the Societyfor Neuroscience, Phoenix, Ariz, November 2, 1989.

Reprint requests to Department of Psychiatry, St Mary's HospitalCenter, 3830 Lacombe Ave, Montreal, Quebec, Canada H3T1M5 (DrBradwejn).

Add to CiteULike CiteULike Add to Connotea Connotea Add to Delicious Delicious Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pentagastrin-induced hemoconcentration in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol
Le Melledo et al.
J Psychopharmacol 2011;25:71-77.
ABSTRACT

One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: Investigation of neural correlates with BOLD MRI
Schunck et al.
J Psychopharmacol 2011;25:52-59.
ABSTRACT

CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects
Maron et al.
J Psychopharmacol 2009;23:460-464.
ABSTRACT

Altered Cerebral {gamma}-Aminobutyric Acid Type A-Benzodiazepine Receptor Binding in Panic Disorder Determined by [11C]Flumazenil Positron Emission Tomography
Hasler et al.
Arch Gen Psychiatry 2008;65:1166-1175.
ABSTRACT | FULL TEXT

Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.
Chen et al.
Proc. Natl. Acad. Sci. USA 2006;103:3881-3886.
ABSTRACT | FULL TEXT

Central Cholecystokinin Activity in Irritable Bowel Syndrome, Panic Disorder, and Healthy Controls
Koszycki et al.
Psychosom. Med. 2005;67:590-595.
ABSTRACT | FULL TEXT

Cognitive Modulation of the Endocrine Stress Response to a Pharmacological Challenge in Normal and Panic Disorder Subjects
Abelson et al.
Arch Gen Psychiatry 2005;62:668-675.
ABSTRACT | FULL TEXT

The Effect of 5-Hydroxytryptophan on Cholecystokinin-4-Induced Panic Attacks in Healthy Volunteers
Maron et al.
J Psychopharmacol 2004;18:194-199.
ABSTRACT

A 28-Year-Old Woman With Panic Disorder
Gorman
JAMA 2001;286:450-457.
FULL TEXT

Anxiolyticlike Effects of Atrial Natriuretic Peptide on Cholecystokinin Tetrapeptide-Induced Panic Attacks: Preliminary Findings
Wiedemann et al.
Arch Gen Psychiatry 2001;58:371-377.
ABSTRACT | FULL TEXT

International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors
Noble et al.
Pharmacol. Rev. 1999;51:745-781.
ABSTRACT | FULL TEXT

Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers
Shlik et al.
J Psychopharmacol 1999;13:385-390.
ABSTRACT

Decreased Brain GABAA-Benzodiazepine Receptor Binding in Panic Disorder: Preliminary Results From a Quantitative PET Study
Malizia et al.
Arch Gen Psychiatry 1998;55:715-720.
ABSTRACT | FULL TEXT

Catecholamines and Pathogenesis in Panic Disorder
Heninger
Arch Gen Psychiatry 1998;55:522-523.
FULL TEXT

Premenstrual Dysphoric Disorder and Response to Cholecystokinin-Tetrapeptide
Le Melledo et al.
Arch Gen Psychiatry 1995;52:605-606.
ABSTRACT

The Panicogenic Effects of Cholecystokinin-Tetrapeptide Are Antagonized by L-365,260, a Central Cholecystokinin Receptor Antagonist, in Patients With Panic Disorder
Bradwejn et al.
Arch Gen Psychiatry 1994;51:486-493.
ABSTRACT

The cholecystokinin hypothesis of panic and anxiety disorders: a review
Bradwejn et al.
J Psychopharmacol 1992;6:345-351.
ABSTRACT

| | |